Department
Pharmaceutical Sciences
Education & Training
- Arkansas Tech University, B.S. Chemistry
- University of Arkansas for Medical Sciences College of Pharmacy, Pharm.D.
- University of Arkansas for Medical Sciences Graduate School, Ph.D. Pharmacology
- University of Arkansas for Medical Sciences, Dept. of Pharmacology/Toxicology, Postdoctoral Fellow
Teaching Responsibilities
- PHSC 7201 Pharmacology I
Research & Scholarly Interests
My research interest is focused on learning the techniques and approaches that underscore hypothesis-driven basic and translational cardiovascular/lymphatic pharmacology research. The primary focus is the mechanisms of damage to the lymphatic system during cancer chemotherapy and developing therapeutic strategies to reduce this damage. The laboratory uses techniques such as tissue dissection, enzymatic cell isolation, flow cytometry, vascular functional studies, and gene and protein expression assays. The laboratory also employs both surgical techniques to measure lymph flow in vivo using high-speed optical imaging.
Another area of interest is the potential effects of cardiovascular drugs on lymphatic function. Hypertension has been associated with an increased risk of lymphedema in breast cancer patients. It is unclear whether this increased risk is due to the role of lymphatics in hypertension pathology or the medications used to treat hypertension. Thus we aim to study the effect of antihypertensive agents on lymphatic function and determine the contribution of antihypertensive agents to the development of lymphedema in cancer patients.
Publications
Stolarz AJ, Chhetri B, Jenkins S, Jamshidi-Parsian A, Gandy J, Philips J, Borrelli M, Fologea D, Griffin RJ. Liposome formulation for tumor-targeted drug delivery using radiation therapy. Int. J. Mol. Sci. 2022, 23(19), 11662; DOI.org/10.3390/ijms231911662
Pal S, Rahman J, Mu S, Rusch NJ, Stolarz AJ. Drug-Related Lymphedema: Mechanisms, Mysteries, and Potential Therapies. Frontiers in Pharmacology. 2022; 12: 850586 doi: 10.3389/fphar.2022.850586.
Van S, Garner BG, Pal S, Steed K, Sridharan V, Mu S, Rusch NJ, Stolarz AJ. Dantrolene prevents doxorubicin-induced “calcium leak” and preserves lymph flow in rat mesenteric lymph vessels. Frontiers in Pharmacology Translational Pharmacology. Accepted Aug 5 2021; DOI: 10.3389/fphar.2021.727526
Garner BR, Stolarz AJ, Stuckey D, Sarimollaoglu M, Liu Y, Palade PT, Rusch NJ, Mu S. KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema. Journal of Pharmacology and Experimental Therapeutics. January 2021; 376(1): 40-50; DOI: 10.1124/jpet.120.000121.
Stolarz AJ, Sarimollaoglu M, Fletcher TW, Marecki JC, Klimberg S, Sung RW, Galanzha EI, Zharov VP, Rusch NJ. Doxorubicin inhibition of lymphatic function is mediated by ryanodine receptors. Journal of Pharmacology and Experimental Therapeutics. 2019; 371(2):278-289. jpet.119.257592; DOI: https://doi.org/10.1124/jpet.119.257592. PMID: 31439806
Stolarz AJ, Lakkad M, Klimberg VS, Painter JT. Calcium channel blocker and risk of lymphedema among breast cancer patients: nested case control study. Cancer Epidemiol Biomarkers Prev August 9 2019; 28(11):1809-1815. DOI: 10.1158/1055-9965.EPI-19-0448. PMID: 31399477.
Sarimollaoglu M, Stolarz AJ, Nedosekin DA, Garner BR, Fletcher TW, Galanzha EI, Rusch NJ, Zharov VP. In vivo high-speed microscopy to quantify contractile and flow parameters in lymph vessels. J Biophotonics 2018 Aug; 11(8):e201700126. DOI: 10.1002/jbio.201700126. PMCID: PMC6314807.
https://www.ncbi.nlm.nih.gov/myncbi/amanda.stolarz.1/bibliography/public/